<DOC>
	<DOCNO>NCT02770651</DOCNO>
	<brief_summary>The purpose study evaluate incidence late incomplete stent apposition ( ISA ) un-coverage optical coherence tomography ( OCT ) follow everolimus-eluting stent ( EES ) bioabsorbable polymer ( SYNERGY™ , Boston Scientific , Nattick , MA , USA ) versus zotarolimus-eluting stent ( ZES ) permanent polymer ( Resolute Onyx™ , Medtronic , Santa Rosa , CA , USA ) implantation patient AMI 12 month .</brief_summary>
	<brief_title>Late Stent Strut Apposition Coverage After Drug-Eluting Stent Implantation OCT Patients With AMI</brief_title>
	<detailed_description>It know persistence polymer may affect late/very late safety efficacy drug elute stent ( DES ) although polymer provide reservoir program drug release . Newer durable polymer may enhance biocompatibility seem associate improved clinical outcome . However , still incriminate occurrence inflammation , neo-atherosclerosis , thrombosis . Therefore , investigator evaluate vascular tissue reaction different kind DES implantation high thrombogenic circumstance acute myocardial infarction ( AMI ) .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Acute myocardial infarction include STsegment elevation myocardial infarction ( STEMI ) non STsegment elevation myocardial infarction ( NSTEMI ) treat PCI Patient ≥ 18 year age Patient judge suitable receive antiplatelet drug ASA ticagrelor least 12 month procedure The patient guardian agree study protocol schedule clinical angiographic , OCT follow provide informed consent , approve appropriate Institutional Review Board/Ethical Committee respective clinical site . The patient know hypersensitivity contraindication follow medication : heparin , abciximab , aspirin , ticagrelor , everolimus , zotarolimus , polymer , platinum chromium , cobalt chromium , contrast medium Female childbearing potential unless pregnancy test negative possibly plan become pregnant time enrollment Cardiogenic shock Patient leave ventricular ejection fraction &lt; 30 % Patient leave main disease Patient Instent restenosis ( ISR ) target vessel ( either bare metal stent DES , nontarget vessel ISR permit ) Patient impair renal function ( creatinine &gt; 2.0mg/dL ) Patient inadequate OCT image quality due severe calcification , vessel tortuosity artifact</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>optical coherence tomography</keyword>
	<keyword>everolimus-eluting stent</keyword>
	<keyword>zotarolimus-eluting stent</keyword>
</DOC>